Developer docs
API playgroundTry for free, no card

Search company profiles

Roivant Sciences

Full company profile

uuid00002ii

Namestring
Roivant Sciences
Legal namestring
Roivant Sciences Ltd.
Websiteurl
roivant.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Roivant Sciences Ltd. is a publicly traded (Nasdaq: ROIV) biopharmaceutical company founded in 2014 that develops and commercializes medicines and healthcare technologies through a portfolio of nimble, focused subsidiaries branded as "Vants." Active Vants include Immunovant (anti-FcRn antibodies batoclimab and IMVT-1402 for autoimmune indications), Priovant (brepocitinib, a dual TYK2/JAK1 inhibitor for dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris; in-licensed from Pfizer, which retains a 25% Priovant stake), Pulmovant (mosliciguat, an inhaled sGC activator licensed from Bayer for pulmonary hypertension associated with interstitial lung disease), Genevant Sciences (lipid nanoparticle drug delivery technology), Kinevant Sciences (namilumab for chronic pulmonary sarcoidosis), and Roivant Discovery (computational drug discovery built on the acquired Silicon Therapeutics platform). The portfolio historically also included Dermavant (VTAMA/tapinarof cream, divested to Organon for up to $1.2B in October 2024) and Telavant (RVT-3101, divested to Roche for $7.1B in October 2023), with the Genevant/Arbutus patent settlement against Moderna yielding $2.25B in March 2026.

Roivant's core technology stack centers on generative AI for proximity-based drug discovery: VantAI's Neo-1 foundation model (now operating as Proxima after an $80M seed round in January 2026) is described as the first model to simultaneously predict biomolecule structures and generate new molecular glues; PsiThera (spun out December 2025 with a $47.5M Series A) operates the QUAISAR physics-based simulation platform; and Lokavant provides clinical trial intelligence for protocol and enrollment optimization. The company reports 12 positive Phase 3 clinical trial readouts since 2019 and 8 FDA approvals across its portfolio.

Roivant monetizes through a hybrid model combining (i) outright subsidiary divestitures to large pharma (Roche, Organon), (ii) licensing and milestone economics on out-licensed assets and technology platforms (Bayer, BMS ~$674M, Blueprint ~$1.67B, Halda $1B, J&J multibillion-dollar Proxima collaboration, Epitopea up to $123.5M), (iii) patent litigation settlements (the $2.25B Moderna/Arbutus LNP settlement), and (iv) capital markets activity including $1.5B (2024) and $1B (2026) share repurchase programs alongside a Roivant-led $550M Immunovant financing in December 2025. The company is transitioning toward direct US commercialization of brepocitinib in dermatomyositis (expected end of September 2026, contingent on FDA Priority Review with a Q3 2026 PDUFA) while retaining a $4.3B cash position and a roughly $20.84B market capitalization, supported by a leadership team headed by CEO Matt Gline, President & CIO Mayukh Sukhatme, and Vant Chair Frank Torti.

Short descriptiontext

Roivant Sciences (Nasdaq: ROIV) is a biopharmaceutical company that develops and commercializes medicines and healthcare technologies through a portfolio of focused subsidiaries ("Vants"), with late-stage immunology assets (brepocitinib, IMVT-1402), an LNP delivery platform validated by a $2.25B Moderna settlement, and AI-driven drug-discovery platforms serving autoimmune and pulmonary disease patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical drug development, autoimmune disease therapeutics, clinical stage pipeline, venture subsidiary pharma model, AI drug discovery
Product category
Biopharmaceutical Drug Development
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical product sales and royalties
TypeSubscription Recurring
Description

Revenue generated from commercialization of proprietary drugs such as brepocitinib (autoimmune diseases including dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, lichen planopilaris, rheumatoid arthritis, Graves' disease, myasthenia gravis, CIDP, Sjögren's, thyroid eye disease) and IMVT-1402. Includes royalty streams from licensed products.

2Subsidiary divestitures / asset sales
TypeOne Time License
Description

Outright divestitures of Roivant-owned subsidiaries to large pharma: Telavant sold to Roche for $7.1B (2023) and Dermavant/VTAMA sold to Organon for $1.2B. These are large, one-time transaction events that have historically driven significant cash inflows.

3Licensing royalties and milestone payments
TypeLicensing Royalties
Description

Recurring and milestone-based licensing revenue from out-licensed pipeline assets and platforms — including Bayer's licensing of mosliciguat to Pulmovant ($14M upfront, up to $280M milestones, total up to $294M), Genevant LNP license to Epitopea (up to $123.5M), and VantAI deals with Bristol Myers Squibb (~$674M) and Halda Therapeutics ($1B).

4Patent settlement payments
TypeOne Time License
Description

Lump-sum payments arising from patent litigation settlements — most notably the $2.25B patent settlement with Moderna (jointly litigated with Arbutus Biopharma) involving Genevant's LNP technology.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Vant
Description

Roivant's branded business model of building nimble, focused subsidiary companies (called "Vants") to develop and commercialize medicines and technologies. Used as a suffix in subsidiary names (e.g., Priovant, Pulmovant, Genevant).

roivant.com
+2 more records
Core offering1 text field

Roivant Sciences develops and commercializes biopharmaceutical medicines through a portfolio of focused, nimble subsidiaries called "Vants," each advancing drugs or technology platforms in specific therapeutic or technology areas. Its current pipeline includes brepocitinib (TYK2/JAK1 inhibitor) in autoimmune diseases, IMVT-1402 and batoclimab (FcRn inhibitors) in autoimmune diseases, mosliciguat (inhaled sGC activator) for pulmonary hypertension associated with interstitial lung disease, and namilumab for sarcoidosis, alongside drug delivery and AI discovery platforms such as Genevant LNP and Roivant Discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 12 positive Phase 3 clinical trial readouts since 2019
+4 more records
Product overview1 text field

Roivant Sciences operates a hub-and-spoke biopharmaceutical platform that develops transformative medicines and technologies by building agile, focused subsidiaries called "Vants." The portfolio spans multiple therapeutic areas including immunology, dermatology, and pulmonary diseases through key subsidiaries: Immunovant (developing FcRn inhibitors batoclimab and IMVT-1402 for autoimmune diseases), Priovant (developing brepocitinib, a dual TYK2/JAK1 inhibitor, across dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris), Pulmovant (developing mosliciguat, an inhaled sGC activator for PH-ILD), and Genevant Sciences (lipid nanoparticle delivery technology platform). The model also includes technology platforms such as VantAI (now Proxima, AI-driven drug discovery), PsiThera (computational chemistry for inflammatory diseases), and Lokavant (clinical trial intelligence). Previously developed products include VTAMA (tapinarof cream for plaque psoriasis, sold to Organon in 2024) and RVT-3101/Telavant (anti-TL1A antibody sold to Roche for $7.1B in 2023).

Product and service7 records
1Brepocitinib (Priovant)
CategoryAutoimmune disease therapeutics
Description

Dual TYK2/JAK1 inhibitor being developed for multiple autoimmune indications including dermatomyositis (NDA-stage with FDA Priority Review and Breakthrough Therapy Designation in cutaneous sarcoidosis), non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris; developed by Priovant Therapeutics, in which Pfizer holds a 25% equity stake.

2IMVT-1402 (Immunovant)
CategoryAutoimmune disease therapeutics
Description

Next-generation anti-FcRn monoclonal antibody being developed by Immunovant for multiple autoimmune indications including Graves' disease, myasthenia gravis, CIDP, Sjogren's syndrome, and rheumatoid arthritis.

3Batoclimab (Immunovant)
CategoryAutoimmune disease therapeutics
Description

Anti-FcRn monoclonal antibody developed by Immunovant for autoimmune indications including myasthenia gravis and thyroid eye disease.

4Mosliciguat (Pulmovant)
CategoryPulmonary disease therapeutics
Description

Inhaled, once-daily soluble guanylate cyclase (sGC) activator in development for pulmonary hypertension associated with interstitial lung disease (PH-ILD), representing approximately 200,000 patients in the US and Europe. Phase 2 PHocus trial enrollment completed with topline data expected H2 2026.

5Namilumab (Kinevant Sciences)
CategoryPulmonary disease therapeutics
Description

Anti-GM-CSF monoclonal antibody developed by Kinevant Sciences for chronic pulmonary sarcoidosis, with the RESOLVE-Lung Phase 2 study fully enrolled.

6Genevant Sciences LNP delivery platform
CategoryDrug delivery technology platform
Description

Proprietary lipid nanoparticle (LNP) drug delivery technology for nucleic acid therapeutics, validated by the $2.25B Moderna patent settlement and licensed to Epitopea for RNA-based cancer immunotherapies.

7Roivant Discovery computational drug discovery platform
CategoryDrug discovery technology platform
Description

Internal drug discovery platform led by CTO Huafeng Xu combining physics-based simulation methods, free energy calculations, structural immunology, and AI to advance Roivant's pipeline.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Roivant in-licensed brepocitinib from Pfizer. Pfizer holds a 25% stake in Telavant (Roivant's subsidiary that was subsequently sold to Roche for $7.1B). RVT-3101 was in-licensed from Pfizer as well. Pfizer is a foundational pipeline source and a major transaction counterparty.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

In December 2023, Roche acquired Roivant's subsidiary Telavant for $7.1B, one of the largest transactions in Roivant's history and the source of significant cash and recognition.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Organon acquired Roivant's Dermavant subsidiary (including VTAMA/tapinarof cream) for $1.2B and assumed global commercial responsibility for the product.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Bayer licensed mosliciguat from Roivant's Pulmovant subsidiary for $14M upfront plus up to $280M in milestones (total deal up to $294M).

5Bristol Myers Squibb
Strategic tierMajorTypeStrategic or Co-development Partner
Description

BMS entered into a partnership with Roivant's VantAI platform valued at approximately $674M for the discovery and development of molecular glues.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

VantAI entered a $1B RIPTAC (regulated induced proximity targeting chimera) partnership with Halda Therapeutics leveraging VantAI's generative AI capabilities.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Epitopea licensed Genevant's lipid nanoparticle (LNP) technology in a deal worth up to $123.5M in upfront and milestone payments.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Roivant (alongside Arbutus Biopharma) settled patent litigation with Moderna over LNP technology for $2.25B, validating Genevant's IP estate.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-plaintiff with Roivant in the LNP patent litigation against Moderna that concluded in the $2.25B settlement.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Sumitomo Pharma returned its stake to Roivant for $648M and subsequently entered a 2019 partnership with Roivant valued at $3B.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Roivant established a partnership with Adimab.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Johnson & Johnson entered a research collaboration with Roivant's Proxima platform for proximity-based therapeutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Blueprint Medicines entered a research collaboration with Roivant's Proxima platform for proximity-based therapeutics.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Closely comparable to Roivant's Vant model — BridgeBio operates multiple focused subsidiaries across rare disease therapeutic areas with a similar strategy of in-licensing and developing de-risked assets; both are public mid-cap biopharmacentric companies with subsidiary-driven structures.

TypeDirect peer
Description

Co-plaintiff with Roivant/Genevant in the $2.25B Moderna LNP patent settlement and itself focused on LNP delivery technology for nucleic acid therapeutics; directly comparable platform technology and litigation-driven revenue profile.

TypeBroad incumbent
Description

Established mid-to-large cap biopharma with similar innovation-driven R&D culture and significant cash reserves funding pipeline expansion; broader portfolio but operates in similar rare/specialty disease areas (CF, sickle cell) with comparable pipeline-to-launch execution capability.

TypeBroad incumbent
Description

Established rare-disease focused biopharma with multiple approved products and ongoing late-stage pipeline development; comparable in therapeutic area focus (rare autoimmune/genetic) and capital allocation approach to specialized disease pipelines.

TypeDirect peer
Description

Clinical-to-commercial stage rare disease biopharma with multiple late-stage programs and a focused pipeline approach; comparable in therapeutic area breadth (immunology/rare disease) and stage of transition from clinical to commercial.

TypeBroad incumbent
Description

Major immunology-focused biopharma competing in autoimmune/inflammatory disease indications where brepocitinib and IMVT-1402 are targeted; broader Dupixent franchise directly competes with Roivant's immunology pipeline.

TypeEmerging player
Description

Computational drug discovery platform company comparable to Roivant Discovery / Silicon Therapeutics; both leverage physics-based computational methods and AI for small molecule discovery with similar biotech platform business models.

TypeEmerging player
Description

AI-driven drug discovery platform comparable to Roivant's VantAI/Proxima platform; both apply machine learning to drug discovery and have multiple pharma partnerships; Recursion is more public-market focused as an AI biotech.

TypeEmerging player
Description

Targeted protein degradation pioneer with PROTAC platform directly comparable to Roivant's Proxima proximity-based therapeutics platform; both pursue novel small-molecule degraders with pharma partnerships (BMS, Pfizer for Arvinas).

TypeEmerging player
Description

Molecular glue degrader platform comparable to VantAI/Proxima Neo-1 platform; both develop proximity-inducing small molecules for immunology and oncology indications with major pharma partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles22 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment11 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Roivant Sciences

Biopharmaceutical Drug Developmentroivant.com

Roivant Sciences (Nasdaq: ROIV) is a biopharmaceutical company that develops and commercializes medicines and healthcare technologies through a portfolio of focused subsidiaries ("Vants"), with late-stage immunology assets (brepocitinib, IMVT-1402), an LNP delivery platform validated by a $2.25B Moderna settlement, and AI-driven drug-discovery platforms serving autoimmune and pulmonary disease patients.

What Roivant Sciences does

Roivant Sciences Ltd. is a publicly traded (Nasdaq: ROIV) biopharmaceutical company founded in 2014 that develops and commercializes medicines and healthcare technologies through a portfolio of nimble, focused subsidiaries branded as "Vants." Active Vants include Immunovant (anti-FcRn antibodies batoclimab and IMVT-1402 for autoimmune indications), Priovant (brepocitinib, a dual TYK2/JAK1 inhibitor for dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris; in-licensed from Pfizer, which retains a 25% Priovant stake), Pulmovant (mosliciguat, an inhaled sGC activator licensed from Bayer for pulmonary hypertension associated with interstitial lung disease), Genevant Sciences (lipid nanoparticle drug delivery technology), Kinevant Sciences (namilumab for chronic pulmonary sarcoidosis), and Roivant Discovery (computational drug discovery built on the acquired Silicon Therapeutics platform). The portfolio historically also included Dermavant (VTAMA/tapinarof cream, divested to Organon for up to $1.2B in October 2024) and Telavant (RVT-3101, divested to Roche for $7.1B in October 2023), with the Genevant/Arbutus patent settlement against Moderna yielding $2.25B in March 2026.

Roivant's core technology stack centers on generative AI for proximity-based drug discovery: VantAI's Neo-1 foundation model (now operating as Proxima after an $80M seed round in January 2026) is described as the first model to simultaneously predict biomolecule structures and generate new molecular glues; PsiThera (spun out December 2025 with a $47.5M Series A) operates the QUAISAR physics-based simulation platform; and Lokavant provides clinical trial intelligence for protocol and enrollment optimization. The company reports 12 positive Phase 3 clinical trial readouts since 2019 and 8 FDA approvals across its portfolio.

Roivant monetizes through a hybrid model combining (i) outright subsidiary divestitures to large pharma (Roche, Organon), (ii) licensing and milestone economics on out-licensed assets and technology platforms (Bayer, BMS ~$674M, Blueprint ~$1.67B, Halda $1B, J&J multibillion-dollar Proxima collaboration, Epitopea up to $123.5M), (iii) patent litigation settlements (the $2.25B Moderna/Arbutus LNP settlement), and (iv) capital markets activity including $1.5B (2024) and $1B (2026) share repurchase programs alongside a Roivant-led $550M Immunovant financing in December 2025. The company is transitioning toward direct US commercialization of brepocitinib in dermatomyositis (expected end of September 2026, contingent on FDA Priority Review with a Q3 2026 PDUFA) while retaining a $4.3B cash position and a roughly $20.84B market capitalization, supported by a leadership team headed by CEO Matt Gline, President & CIO Mayukh Sukhatme, and Vant Chair Frank Torti.

Roivant Sciences firmographics

Firmographics
Name
Roivant Sciences
Legal name
Roivant Sciences Ltd.
Website
https://roivant.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Roivant Sciences (Nasdaq: ROIV) is a biopharmaceutical company that develops and commercializes medicines and healthcare technologies through a portfolio of focused subsidiaries ("Vants"), with late-stage immunology assets (brepocitinib, IMVT-1402), an LNP delivery platform validated by a $2.25B Moderna settlement, and AI-driven drug-discovery platforms serving autoimmune and pulmonary disease patients.
Ownership category
akta.pro rank

Where Roivant Sciences is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Roivant Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical product sales and royalties: Revenue generated from commercialization of proprietary drugs such as brepocitinib (autoimmune diseases including dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, lichen planopilaris, rheumatoid arthritis, Graves' disease, myasthenia gravis, CIDP, Sjögren's, thyroid eye disease) and IMVT-1402. Includes royalty streams from licensed products.
  2. Subsidiary divestitures / asset sales: Outright divestitures of Roivant-owned subsidiaries to large pharma: Telavant sold to Roche for $7.1B (2023) and Dermavant/VTAMA sold to Organon for $1.2B. These are large, one-time transaction events that have historically driven significant cash inflows.
  3. Licensing royalties and milestone payments: Recurring and milestone-based licensing revenue from out-licensed pipeline assets and platforms — including Bayer's licensing of mosliciguat to Pulmovant ($14M upfront, up to $280M milestones, total up to $294M), Genevant LNP license to Epitopea (up to $123.5M), and VantAI deals with Bristol Myers Squibb (~$674M) and Halda Therapeutics ($1B).
  4. Patent settlement payments: Lump-sum payments arising from patent litigation settlements — most notably the $2.25B patent settlement with Moderna (jointly litigated with Arbutus Biopharma) involving Genevant's LNP technology.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Roivant Sciences product offering

Product offering

Core offering

Roivant Sciences develops and commercializes biopharmaceutical medicines through a portfolio of focused, nimble subsidiaries called "Vants," each advancing drugs or technology platforms in specific therapeutic or technology areas. Its current pipeline includes brepocitinib (TYK2/JAK1 inhibitor) in autoimmune diseases, IMVT-1402 and batoclimab (FcRn inhibitors) in autoimmune diseases, mosliciguat (inhaled sGC activator) for pulmonary hypertension associated with interstitial lung disease, and namilumab for sarcoidosis, alongside drug delivery and AI discovery platforms such as Genevant LNP and Roivant Discovery.

Product overview

Roivant Sciences operates a hub-and-spoke biopharmaceutical platform that develops transformative medicines and technologies by building agile, focused subsidiaries called "Vants." The portfolio spans multiple therapeutic areas including immunology, dermatology, and pulmonary diseases through key subsidiaries: Immunovant (developing FcRn inhibitors batoclimab and IMVT-1402 for autoimmune diseases), Priovant (developing brepocitinib, a dual TYK2/JAK1 inhibitor, across dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris), Pulmovant (developing mosliciguat, an inhaled sGC activator for PH-ILD), and Genevant Sciences (lipid nanoparticle delivery technology platform). The model also includes technology platforms such as VantAI (now Proxima, AI-driven drug discovery), PsiThera (computational chemistry for inflammatory diseases), and Lokavant (clinical trial intelligence). Previously developed products include VTAMA (tapinarof cream for plaque psoriasis, sold to Organon in 2024) and RVT-3101/Telavant (anti-TL1A antibody sold to Roche for $7.1B in 2023).

Differentiator

Problem solved

Functional benefit

Brands

  • Vant: Roivant's branded business model of building nimble, focused subsidiary companies (called "Vants") to develop and commercialize medicines and technologies. Used as a suffix in subsidiary names (e.g., Priovant, Pulmovant, Genevant).
  • Roivant Discovery
  • Roivant Health

Products and services

  • Brepocitinib (Priovant) Dual TYK2/JAK1 inhibitor being developed for multiple autoimmune indications including dermatomyositis (NDA-stage with FDA Priority Review and Breakthrough Therapy Designation in cutaneous sarcoidosis), non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris; developed by Priovant Therapeutics, in which Pfizer holds a 25% equity stake.
  • IMVT-1402 (Immunovant) Next-generation anti-FcRn monoclonal antibody being developed by Immunovant for multiple autoimmune indications including Graves' disease, myasthenia gravis, CIDP, Sjogren's syndrome, and rheumatoid arthritis.
  • Batoclimab (Immunovant) Anti-FcRn monoclonal antibody developed by Immunovant for autoimmune indications including myasthenia gravis and thyroid eye disease.
  • Mosliciguat (Pulmovant) Inhaled, once-daily soluble guanylate cyclase (sGC) activator in development for pulmonary hypertension associated with interstitial lung disease (PH-ILD), representing approximately 200,000 patients in the US and Europe. Phase 2 PHocus trial enrollment completed with topline data expected H2 2026.
  • Namilumab (Kinevant Sciences) Anti-GM-CSF monoclonal antibody developed by Kinevant Sciences for chronic pulmonary sarcoidosis, with the RESOLVE-Lung Phase 2 study fully enrolled.
  • Genevant Sciences LNP delivery platform Proprietary lipid nanoparticle (LNP) drug delivery technology for nucleic acid therapeutics, validated by the $2.25B Moderna patent settlement and licensed to Epitopea for RNA-based cancer immunotherapies.
  • Roivant Discovery computational drug discovery platform Internal drug discovery platform led by CTO Huafeng Xu combining physics-based simulation methods, free energy calculations, structural immunology, and AI to advance Roivant's pipeline.

Quantifiable outcome

  • 12 positive Phase 3 clinical trial readouts since 2019
  • +4 more outcomes

Companies that use Roivant Sciences

Customer profile

Segments4 records

Ideal customer profiles2 records

Roivant Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability9 records

Feature5 records

Roivant Sciences partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship, major, core and minor.

  • PfizerflagshipStrategic or Co-development PartnerRoivant in-licensed brepocitinib from Pfizer. Pfizer holds a 25% stake in Telavant (Roivant's subsidiary that was subsequently sold to Roche for $7.1B). RVT-3101 was in-licensed from Pfizer as well. Pfizer is a foundational pipeline source and a major transaction counterparty.
  • RocheflagshipStrategic or Co-development PartnerIn December 2023, Roche acquired Roivant's subsidiary Telavant for $7.1B, one of the largest transactions in Roivant's history and the source of significant cash and recognition.
  • OrganonmajorChannel Partner/ Reseller/ DistributorOrganon acquired Roivant's Dermavant subsidiary (including VTAMA/tapinarof cream) for $1.2B and assumed global commercial responsibility for the product.
  • BayermajorStrategic or Co-development PartnerBayer licensed mosliciguat from Roivant's Pulmovant subsidiary for $14M upfront plus up to $280M in milestones (total deal up to $294M).
  • Bristol Myers SquibbmajorStrategic or Co-development PartnerBMS entered into a partnership with Roivant's VantAI platform valued at approximately $674M for the discovery and development of molecular glues.
  • Halda TherapeuticsmajorStrategic or Co-development PartnerVantAI entered a $1B RIPTAC (regulated induced proximity targeting chimera) partnership with Halda Therapeutics leveraging VantAI's generative AI capabilities.
  • EpitopeacoreOEM/ Whitelabel/ Licensing PartnerEpitopea licensed Genevant's lipid nanoparticle (LNP) technology in a deal worth up to $123.5M in upfront and milestone payments.
  • ModernaflagshipStrategic or Co-development PartnerRoivant (alongside Arbutus Biopharma) settled patent litigation with Moderna over LNP technology for $2.25B, validating Genevant's IP estate.
  • Arbutus BiopharmacoreStrategic or Co-development PartnerCo-plaintiff with Roivant in the LNP patent litigation against Moderna that concluded in the $2.25B settlement.
  • Sumitomo PharmamajorStrategic or Co-development PartnerSumitomo Pharma returned its stake to Roivant for $648M and subsequently entered a 2019 partnership with Roivant valued at $3B.
  • AdimabminorStrategic or Co-development PartnerRoivant established a partnership with Adimab.
  • Johnson & JohnsoncoreStrategic or Co-development PartnerJohnson & Johnson entered a research collaboration with Roivant's Proxima platform for proximity-based therapeutics.
  • Blueprint MedicinescoreStrategic or Co-development PartnerBlueprint Medicines entered a research collaboration with Roivant's Proxima platform for proximity-based therapeutics.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

Roivant Sciences competitors and assessment

Company assessment

Direct peers

  • BridgeBio Pharma: Closely comparable to Roivant's Vant model — BridgeBio operates multiple focused subsidiaries across rare disease therapeutic areas with a similar strategy of in-licensing and developing de-risked assets; both are public mid-cap biopharmacentric companies with subsidiary-driven structures.
  • Arbutus Biopharma: Co-plaintiff with Roivant/Genevant in the $2.25B Moderna LNP patent settlement and itself focused on LNP delivery technology for nucleic acid therapeutics; directly comparable platform technology and litigation-driven revenue profile.
  • Ultragenyx Pharmaceutical: Clinical-to-commercial stage rare disease biopharma with multiple late-stage programs and a focused pipeline approach; comparable in therapeutic area breadth (immunology/rare disease) and stage of transition from clinical to commercial.

Broad incumbents

  • Vertex Pharmaceuticals: Established mid-to-large cap biopharma with similar innovation-driven R&D culture and significant cash reserves funding pipeline expansion; broader portfolio but operates in similar rare/specialty disease areas (CF, sickle cell) with comparable pipeline-to-launch execution capability.
  • BioMarin Pharmaceutical: Established rare-disease focused biopharma with multiple approved products and ongoing late-stage pipeline development; comparable in therapeutic area focus (rare autoimmune/genetic) and capital allocation approach to specialized disease pipelines.
  • Regeneron Pharmaceuticals: Major immunology-focused biopharma competing in autoimmune/inflammatory disease indications where brepocitinib and IMVT-1402 are targeted; broader Dupixent franchise directly competes with Roivant's immunology pipeline.

Emerging players

  • Schrödinger: Computational drug discovery platform company comparable to Roivant Discovery / Silicon Therapeutics; both leverage physics-based computational methods and AI for small molecule discovery with similar biotech platform business models.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform comparable to Roivant's VantAI/Proxima platform; both apply machine learning to drug discovery and have multiple pharma partnerships; Recursion is more public-market focused as an AI biotech.
  • Arvinas: Targeted protein degradation pioneer with PROTAC platform directly comparable to Roivant's Proxima proximity-based therapeutics platform; both pursue novel small-molecule degraders with pharma partnerships (BMS, Pfizer for Arvinas).
  • Kymera Therapeutics: Molecular glue degrader platform comparable to VantAI/Proxima Neo-1 platform; both develop proximity-inducing small molecules for immunology and oncology indications with major pharma partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Roivant Sciences social profiles

Digital presence

Roivant Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Roivant Sciences leadership team

Management profile

Number of profiles

Profiles22 records

Roivant Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Roivant Sciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Roivant Sciences M&A and investment

M&A and investment

M&A3 records

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roivant Sciences

What does Roivant Sciences do?

Roivant Sciences develops and commercializes biopharmaceutical medicines through a portfolio of focused, nimble subsidiaries called "Vants," each advancing drugs or technology platforms in specific therapeutic or technology areas. Its current pipeline includes brepocitinib (TYK2/JAK1 inhibitor) in autoimmune diseases, IMVT-1402 and batoclimab (FcRn inhibitors) in autoimmune diseases, mosliciguat (inhaled sGC activator) for pulmonary hypertension associated with interstitial lung disease, and namilumab for sarcoidosis, alongside drug delivery and AI discovery platforms such as Genevant LNP and Roivant Discovery.

Is Roivant Sciences a public or private company?

Roivant Sciences is a public company. It is classified as public and is currently operating.

When was Roivant Sciences founded?

Roivant Sciences was founded in 2014. It employs 101 to 250 people.

Where is Roivant Sciences based?

Roivant Sciences is headquartered in New York, United States, in the North America region.

How does Roivant Sciences make money?

Four revenue lines are on record. Pharmaceutical product sales and royalties are the primary driver. The others are subsidiary divestitures / asset sales, licensing royalties and milestone payments and patent settlement payments.

Who are Roivant Sciences's main competitors?

Direct peers on record are BridgeBio Pharma, Arbutus Biopharma and Ultragenyx Pharmaceutical. Broad incumbents are Vertex Pharmaceuticals, BioMarin Pharmaceutical and Regeneron Pharmaceuticals. Emerging players are Schrödinger, Recursion Pharmaceuticals, Arvinas and Kymera Therapeutics.

Does Roivant Sciences have an API?

No public API is recorded for Roivant Sciences.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaRoivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 TranscriptRoivant Sciences CEO Matthew Gline discussed the company's 2026 progress at a Jefferies conference, citing positive Phase II data in cutaneous sarcoid and LPP as a Phase II/III candidate. He noted the year was quiet but set the stage for brepo registration and an upcoming Investor Day.Investing.comImmunovant director Atul Pande sells $108,000 in stockImmunovant director Atul Pande sold 3,000 shares for $108,000 on November 11, 2026, after exercising options at $8.43 each. The sale was part of a Rule 10b5-1 plan, and he now holds 116,731 shares directly and 20,000 indirectly. Roivant Sciences reported a smaller-than-expected Q2 loss, with LISRAYA generating $31 million in revenue.American Banking and Market NewsRoivant Sciences (NASDAQ:ROIV) Stock Gets Price Target Bump from HC WainwrightHC Wainwright raised its price target on Roivant Sciences from $47 to $48, keeping a buy rating. The stock opened at $41.85, and CEO Eric Venker sold 200,000 shares at $35.11. Analysts' consensus is a Moderate Buy with an average target of $46.64.The future of tradingRoivant's Brepocitinib Achieves Clear or Almost Clear Skin in 69% of Cutaneous Sarcoidosis Patients in Phase 2 TrialRoivant published Phase 2 brepocitinib results in JAMA Dermatology, showing improved skin disease activity versus placebo in cutaneous sarcoidosis. Patients reported better skin-related quality of life; treatment was well tolerated over 16 weeks with no serious adverse events. Results will be presented at ACR Convergence 2026, supporting the ongoing Phase 3 BEACON+ trial with topline data expected in 2028.Defense WorldRoivant Sciences Ltd. $ROIV Stock: CenterBook Partners LP Cuts PositionCenterBook Partners LP cut its Roivant Sciences stake by 35.6% in Q3, selling 18,928 shares and leaving with 34,188 shares. Other institutions added positions, while insiders sold shares worth $73.4 million in 90 days. Analysts rate the stock a Moderate Buy with a $46.55 price target.American Banking and Market NewsCenterBook Partners LP Sells 18,928 Shares of Roivant Sciences Ltd. $ROIVCenterBook Partners LP reduced its Roivant Sciences stake by 35.6% in Q3, selling 18,928 shares and leaving with 34,188 shares worth $1.25 million. Other institutional investors also adjusted positions, and analysts rate the stock a Moderate Buy with a $46.55 price target.The Motley FoolRoivant Sciences (ROIV) Q2 2026 Earnings Call TranscriptRoivant reported Q2 2026 results, including $31 million in LISRAYA revenue from its first five weeks of commercial launch. The company also presented positive clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib in noninfectious uveitis, with a $4.2 billion cash position. Management indicated ongoing FDA discussions for IMVT-1402's registrational path.The Motley FoolRoivant Sciences (ROIV) Q2 2026 Earnings Call TranscriptRoivant reported Q2 2026 results, including $31 million in LISRAYA revenue from its first five weeks of commercial launch. The company also presented positive Phase 3 data for IMVT-1402 in rheumatoid arthritis, with a 92.5% ACR20 response at week 28 versus 75.6% for placebo. Cash and marketable securities stood at $4.2 billion as of September 30, 2026.Seeking AlphaRoivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call TranscriptRoivant Sciences held its Q2 2026 earnings call on November 9, 2026, with CEO Matthew Gline and COO Stephanie Lee Griffin presenting results for the quarter ended September 30, 2026. The call included forward-looking statements, and the company provided slides and a press release on its IR website.MarketBeatRoivant Sciences Q2 Earnings Call HighlightsRoivant Sciences reported $31 million in net revenue from LISRAYA's initial launch and a $153 million net loss for Q2 2026. The company also said its rheumatoid arthritis drug met its primary endpoint in a randomized withdrawal study. It expects inventory effects to become less relevant next year.